Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 31, 2011

Amgen to Appeal EMA’s Negative Opinion on Vectibix Combination with Chemotherapy

Amgen to Appeal EMA’s Negative Opinion on Vectibix Combination with Chemotherapy

Firm claims clinical trials demonstrate combining drug with chemotherapy boosts progression-free survival.[krishnacreations-Fotolia.com]

  • Amgen has confirmed that it will formally appeal against the European Medicines Agency’s recent recommendation against extending the marketing authorization for Vectibix® (panitumumab) to include combination with chemotherapy for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC).

    The firm maintains that clinical trials have clearly shown that adding Vectibix to FOLFOX or FOLFIRI chemotherapy improved progression-free survival when compared with chemotherapy alone in patients with wild-type KRAS mCRC.

    Vectibix is already approved in more than 30 countries outside the U.S. as monotherapy for patients with wild-type KRAS mCRC when standard chemotherapy is no longer effective. In the U.S., Vectibix received accelerated approval in September 2006 as a monotherapy for the treatment of patients with EGFR-expressing mCRC after disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. In Japan and Israel, Vectibix is approved for use in combination with chemotherapy for patients with wild-type KRAS mCRC.



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »